Skip to content

Author

N. Florez

We have 6 of 193 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Cancer-related fatigue as partial mediator of the effect of a remotely delivered exercise intervention on health-related quality of life: Phase II randomized trial.

276 Background: Patients receiving immunotherapy frequently experience cancer-related fatigue, symptom burden, and impaired health-related quality of life (HRQOL). Although exercise can improve patient-reported outcomes, the mechanisms underlying its effects remain unclear; this study evaluated whether reductio...

P. G. Bergerot, C. Bergerot, P. W. Schorn et al. · 0 citations
Aug 2026

Tumor mutational burden as a predictor of immune-related adverse events in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors: a Brief Report.

BACKGROUND Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...

F. Pecci, Xinan Wang, Valentina Santo et al. · 0 citations
Review Open access Sep 2026

Independent cancer research in low- and middle-income countries: why it matters and how to build it

A descriptive analysis of oncology trials registered on ClinicalTrials.gov is presented and strategies to enhance international collaboration and amplify LMIC participation in setting global cancer research priorities are proposed.

O. Arrieta, E. Rios-Garcia, Cittim B. Palomares-Palomares et al. · 0 citations
Open access Jul 2026

Germline determinants of risk and molecular subtype in young-onset lung cancer

A complex germline architecture underlying susceptibility and molecular subtype in young-onset lung cancer is delineated, consistent with additive risk from rare and common variants.

J. LoPiccolo, Ryan L. Collins, Noah Fields et al. · 0 citations
Aug 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.

F. Facchinetti, L. Friboulet, L. Liao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.